{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:44:25Z","timestamp":1792165465885,"version":"4.4.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Trans women (male sex assigned at birth, female gender identity) mostly use antiandrogens combined with estrogens and can subsequently undergo vaginoplasty including orchiectomy. Because the prostate remains in situ after this procedure, trans women are still at risk for prostate cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the incidence of prostate cancer in trans women using hormone treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>In this nationwide retrospective cohort study, data of participants were linked to the Dutch national pathology database and to Statistics Netherlands to obtain data on prostate cancer diagnosis and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Gender identity clinic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Trans women who visited our clinic between 1972 and 2016 and received hormone treatment were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Standardized incidence ratios (SIRs) were calculated using the number of observed prostate cancer cases in our cohort and the number of expected cases based on age-specific incidence numbers from the Netherlands Comprehensive Cancer Organization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population consisted of 2281 trans women with a median follow-up time of 14 years (interquartile range 7-24), and a total follow-up time of 37\u2005117 years. Six prostate cancer cases were identified after a median 17 years of hormone treatment. This resulted in a lower prostate cancer risk in trans women than in Dutch reference males (SIR 0.20, 95% confidence interval 0.08-0.42).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Trans women receiving androgen deprivation therapy and estrogens have a substantially lower risk for prostate cancer than the general male population. Our results support the hypothesis that androgen deprivation has a preventive effect on the initiation and development of prostate cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa412","type":"journal-article","created":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:13:54Z","timestamp":1593303234000},"page":"e3293-e3299","source":"Crossref","is-referenced-by-count":81,"title":["Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6801-7827","authenticated-orcid":false,"given":"Iris","family":"de Nie","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel J M","family":"de Blok","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim M","family":"van der Sluis","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Barb\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry L S","family":"Pigot","sequence":"additional","affiliation":[{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Department of Urology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M","family":"Wiepjes","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke M","family":"Nota","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah M","family":"van Mello","sequence":"additional","affiliation":[{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Department of Obstetrics and Gynecology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle E","family":"Valkenburg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Huirne","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J G","family":"Gooren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Jeroen A","family":"van Moorselaar","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen M A","family":"Dreijerink","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"den Heijer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"2021122203124426800_CIT0001","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"APA","year":"2013","edition":"5"},{"issue":"4","key":"2021122203124426800_CIT0002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jsxm.2018.01.016","article-title":"The Amsterdam cohort of gender dysphoria study (1972-2015): trends in prevalence, treatment, and regrets","volume":"15","author":"Wiepjes","year":"2018","journal-title":"J Sex Med."},{"issue":"11","key":"2021122203124426800_CIT0003","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122203124426800_CIT0004","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med."},{"key":"2021122203124426800_CIT0005","doi-asserted-by":"crossref","first-page":"j5027","DOI":"10.1136\/bmj.j5027","article-title":"Long term hormonal treatment for transgender people","volume":"359","author":"den Heijer","year":"2017","journal-title":"BMJ."},{"key":"2021122203124426800_CIT0006","doi-asserted-by":"crossref","first-page":"l1652","DOI":"10.1136\/bmj.l1652","article-title":"Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands","volume":"365","author":"de Blok","year":"2019","journal-title":"BMJ."},{"key":"2021122203124426800_CIT0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15532739.2011.700873","article-title":"Standards of care for the health of transsexual, transgender, and gender-nonconforming people, Version 7","volume":"13","author":"Coleman","year":"2012","journal-title":"Int J Transgender Health"},{"issue":"4","key":"2021122203124426800_CIT0008","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMra021562","article-title":"Prostate cancer","volume":"349","author":"Nelson","year":"2003","journal-title":"N Engl J Med."},{"issue":"4","key":"2021122203124426800_CIT0009","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the Prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"issue":"4","key":"2021122203124426800_CIT0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol."},{"issue":"5","key":"2021122203124426800_CIT0011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bju.13417","article-title":"Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis","volume":"118","author":"Boyle","year":"2016","journal-title":"BJU Int."},{"issue":"4","key":"2021122203124426800_CIT0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/15622971003671628","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias","volume":"11","author":"Thibaut","year":"2010","journal-title":"World J Biol Psychiatry."},{"issue":"1","key":"2021122203124426800_CIT0013","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol."},{"key":"2021122203124426800_CIT0014","volume-title":"Non-public","author":"Statistics Netherlands."},{"key":"2021122203124426800_CIT0015"},{"issue":"2","key":"2021122203124426800_CIT0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol."},{"issue":"10","key":"2021122203124426800_CIT0017","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/and.12208","article-title":"Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens","volume":"46","author":"Gooren","year":"2014","journal-title":"Andrologia."},{"issue":"8","key":"2021122203124426800_CIT0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.annepidem.2017.07.007","article-title":"Cohort study of cancer risk among insured transgender people","volume":"27","author":"Silverberg","year":"2017","journal-title":"Ann Epidemiol."},{"issue":"12","key":"2021122203124426800_CIT0019","doi-asserted-by":"crossref","first-page":"e018121","DOI":"10.1136\/bmjopen-2017-018121","article-title":"Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people","volume":"7","author":"Quinn","year":"2017","journal-title":"BMJ Open."},{"issue":"2","key":"2021122203124426800_CIT0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol."},{"issue":"10","key":"2021122203124426800_CIT0021","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1210\/en.2015-1357","article-title":"Stem cells as hormone targets that lead to increased cancer susceptibility","volume":"156","author":"Prins","year":"2015","journal-title":"Endocrinology."},{"issue":"1","key":"2021122203124426800_CIT0022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pros.23446","article-title":"Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression","volume":"78","author":"Bonkhoff","year":"2018","journal-title":"Prostate."},{"key":"2021122203124426800_CIT0023","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2018.00002","article-title":"Estrogens and their receptors in prostate cancer: therapeutic implications","volume":"8","author":"Di Zazzo","year":"2018","journal-title":"Front Oncol."},{"issue":"3","key":"2021122203124426800_CIT0024","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pros.10177","article-title":"Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study","volume":"54","author":"S\u00e1nchez-Chapado","year":"2003","journal-title":"Prostate."},{"issue":"5","key":"2021122203124426800_CIT0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.eururo.2005.08.010","article-title":"The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study","volume":"48","author":"Soos","year":"2005","journal-title":"Eur Urol."},{"issue":"3","key":"2021122203124426800_CIT0026","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.juro.2007.10.057","article-title":"Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors","volume":"179","author":"Yin","year":"2008","journal-title":"J Urol."},{"key":"2021122203124426800_CIT0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urology.2017.08.032","article-title":"Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges","volume":"110","author":"Deebel","year":"2017","journal-title":"Urology."},{"issue":"4","key":"2021122203124426800_CIT0028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1464-410X.2009.08695.x","article-title":"Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways","volume":"104","author":"Vis","year":"2009","journal-title":"BJU Int."},{"issue":"11","key":"2021122203124426800_CIT0029","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.2014.2085","article-title":"Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence","volume":"311","author":"Hayes","year":"2014","journal-title":"JAMA."},{"issue":"4","key":"2021122203124426800_CIT0030","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol."},{"issue":"2","key":"2021122203124426800_CIT0031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa412\/33439099\/dgaa412.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/9\/e3293\/41847138\/jcem_105_9_e3293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/9\/e3293\/41847138\/jcem_105_9_e3293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T03:13:54Z","timestamp":1640142834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/9\/e3293\/5864158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,27]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa412","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,27]]}}}